Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

ARS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, NOV. 26, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC.(NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT THEMSELVES FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED ITS PARTICIPATION AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE, DECEMBER 2-4, 2025, IN NEW YORK.

ARS PHARMACEUTICALS TO PARTICIPATE IN PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

$32.5 MILLION IN REVENUE, INCLUDING $31.3 MILLION IN NEFFY U.S. NET PRODUCT REVENUE IN THIRD QUARTER OF 2025

ARS PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS FOR NEFFY (EPINEPHRINE NASAL SPRAY)

OFFERS NO-HASSLE, FREE VIRTUAL VISIT WITH HEALTHCARE PROVIDER FOR PATIENTS TO RECEIVE NEFFY FOR $0 CO-PAY IF ELIGIBLE WITH COMMERCIAL INSURANCE PROGRAM IS AVAILABLE TO ELIGIBLE PATIENTS WHO MAY ALREADY HAVE AN AUTO-INJECTOR, BUT ARE LOOKING FOR A SMALLER, EASIER TO ADMINISTER OPTION SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT THEMSELVES FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, ANNOUNCED THE LAUNCH OF GET NEFFY ON US, A NEW INTEGRATED COMMERCIAL PROGRAM TO HELP PATIENTS ACCESS THEIR NEEDLE-FREE EPINEPHRINE MEDICINE, NEFFY . GET NEFFY ON US WAS CREATED TO ELIMINATE THE TIME BURDEN OF AN IN-PERSON OFFICE VISIT BY OFFERING A FREE VISIT WITH A VIRTUAL PROVIDER WHO CAN PRESCRIBE NEFFY.

ARS PHARMA LAUNCHES GET NEFFY ON US FOR PATIENTS WITH SEVERE ALLERGIC REACTIONS TO IMPROVE ACCESS TO NEFFY (EPINEPHRINE NASAL SPRAY)

ARS PHARMA TO SHOWCASE A LATE-BREAKING ORAL PRESENTATION AND SIX POSTER PRESENTATIONS HIGHLIGHTING REAL WORLD IMPACT OF NEFFY  (EPINEPHRINE NASAL SPRAY) ORAL PRESENTATION TO REPORT RESULTS FROM REAL WORLD DATA ON THE EFFECTIVENESS OF EPINEPHRINE NASAL SPRAY IN CLINICAL PRACTICE CASE REPORTS TO DETAIL REAL-WORLD DATA AND EFFECTIVE USE OF NEFFY IN PATIENTS WHO EXPERIENCE ANAPHYLAXIS DURING ORAL FOOD CHALLENGES OR ALLERGY IMMUNOTHERAPY SAN DIEGO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM SEVERE ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, ANNOUNCED TODAY THAT ONE LATE-BREAKING ORAL AND SIX POSTER PRESENTATIONS WILL BE FEATURED AT THE 2025 ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY (ACAAI), TAKING PLACE NOVEMBER 6-10, 2025, IN ORLANDO, FL. THE PRESENTATIONS HIGHLIGHT REAL-WORLD EXPERIENCE ASSOCIATED WITH INTRANASAL EPINEPHRINE.

UPDATE -- ARS PHARMA TO PRESENT REAL-WORLD DATA ON INTRANASAL EPINEPHRINE AT 2025 AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY (ACAAI) ANNUAL SCIENTIFIC MEETING

SAN DIEGO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON MONDAY, NOVEMBER 10, 2025, AT 5:30 A.M. PT / 8:30 A.M.

ARS PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR ITS THIRD QUARTER 2025 FINANCIAL RESULTS

ARS PHARMA TO SHOWCASE A LATE-BREAKING ORAL PRESENTATION AND SIX POSTER PRESENTATIONS HIGHLIGHTING REAL WORLD IMPACT OF NEFFY  (EPINEPHRINE NASAL SPRAY)

ARS PHARMA TO PRESENT REAL-WORLD DATA ON INTRANASAL EPINEPHRINE AT 2025 AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY (ACAAI) ANNUAL SCIENTIFIC MEETING

SAN DIEGO, OCT. 08, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THE OPPOSITION DIVISION OF THE EUROPEAN PATENT OFFICE (THE EPO) UPHELD THE VALIDITY OF ALL CLAIMS IN EP 3678649, WHICH IS A PATENT VALIDATED IN OVER 30 EUROPEAN COUNTRIES DIRECTED TO NASAL SPRAY EPINEPHRINE FORMULATIONS INCLUDING ALKYL-GLYCOSIDE, SUCH AS INTRAVAIL, AND USES THEREOF. ARS PHARMA'S ISSUED GLOBAL INTELLECTUAL PROPERTY PORTFOLIO RELATED TO NEFFY PROVIDES COVERAGE UNTIL AT LEAST 2039.

ARS PHARMACEUTICALS RECEIVES FAVORABLE DECISION FROM EUROPEAN PATENT OFFICE ON PATENT RELATED TO NEFFY (EPINEPHRINE NASAL SPRAY)

INITIAL $100 MILLION TERM LOAN TO PROPEL MARKET SHARE GROWTH IN THE U.S. SAN DIEGO, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED IT HAS ENTERED INTO A SENIOR SECURED TERM LOAN FACILITY OF UP TO $250 MILLION WITH AN AFFILIATE OF RA CAPITAL MANAGEMENT (RA CAPITAL), THE COMPANY'S LARGEST SHAREHOLDER, AND AN AFFILIATE OF OMERS LIFE SCIENCES AS LENDERS.

ARS PHARMACEUTICALS SECURES UP TO $250 MILLION LOAN FACILITY WITH RA CAPITAL MANAGEMENT AND OMERS LIFE SCIENCES TO ACCELERATE U.S. COMMERCIALIZATION OF NEFFY

 ACCOMPLISHED BIOPHARMA EXECUTIVE AND ENTREPRENEUR BRINGS A 25-YEAR TRACK RECORD OF UPSCALING VALUABLE COMPANIES AND REALIZING THE POTENTIAL OF THEIR INNOVATIONS  SAN DIEGO, SEPT. 17, 2025 (GLOBE NEWSWIRE) -- ADARX PHARMACEUTICALS, INC. (ADARX), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION RNA THERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF LAURA SHAWVER, PH.D.

ADARX PHARMACEUTICALS APPOINTS INDUSTRY VETERAN, LAURA SHAWVER, PH.D., AS BOARD CHAIR

FINDINGS ACCEPTED FOR PUBLICATION IN THE OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY ABOUT 9 OUT OF EVERY 10 PATIENTS EXPERIENCING ANAPHYLAXIS WERE EFFECTIVELY TREATED WITH A SINGLE DOSE OF NEFFY RESULTS SUGGEST REAL-WORLD EFFECTIVENESS OF NEFFY IS CONSISTENT WITH THAT HISTORICALLY REPORTED FOR EPINEPHRINE INJECTION SAN DIEGO, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY SHARES REAL-WORLD EVIDENCE EVALUATING THE CLINICAL PERFORMANCE OF NEFFY  (EPINEPHRINE NASAL SPRAY) IN PATIENTS EXPERIENCING ANAPHYLAXIS SYMPTOMS DURING ORAL FOOD CHALLENGE AND ALLERGEN IMMUNOTHERAPY.

ARS Pharmaceuticals, Inc.

SPRY

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARS Pharmaceuticals, Inc.

SPRY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SPRY